ProShare Advisors
CALA

ProShare Advisors’s Calithera Biosciences, Inc CALA Stock Holding History

ProShare Advisors’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-792
Closed -$35K – 2358
2021
Q3 		$35K Buy
792
+127
+19% +$5.48K ﹤0.01% 1988
2021
Q2 		$28K Sell
665
-705
-51% -$31K ﹤0.01% 2367
2021
Q1 		$66K Buy
1,370
+97
+8% +$5.64K ﹤0.01% 2209
2020
Q4 		$125K Buy
+1,273
New +$112K ﹤0.01% 1956
2018
Q4 		– Sell
-924
Closed -$97K – 1748
2018
Q3 		$97K Sell
924
-34
-4% -$3.24K ﹤0.01% 1683
2018
Q2 		$96K Sell
958
-58
-6% -$6.57K ﹤0.01% 1713
2018
Q1 		$128K Sell
1,016
-167
-14% -$26K ﹤0.01% 1613
2017
Q4 		$198K Buy
+1,183
New +$303K ﹤0.01% 1645

Other funds holding CALA

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

ProShare Advisors's CALA Position: Q4 2021 in Review

ProShare Advisors sold out of Calithera Biosciences, Inc (CALA) in Q4 2021, closing a stake of 792 shares — an estimated $35K sold.

ProShare Advisors first reported a position in CALA in Q4 2017 and held it in 8 quarters. The position peaked at $198K in Q4 2017. 55 funds tracked by Wall St. Rank hold CALA as of Q4 2021.

  • ProShare Advisors reported no remaining Calithera Biosciences, Inc position as of Q4 2021 after selling out during the quarter.
  • ProShare Advisors sold 792 Calithera Biosciences, Inc shares in Q4 2021, an estimated $35K.
  • ProShare Advisors first reported a position in Calithera Biosciences, Inc in Q4 2017 and held it in 8 quarters.
  • ProShare Advisors's Calithera Biosciences, Inc position peaked at $198K in Q4 2017.
  • 55 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q4 2021.

Based on ProShare Advisors's 13F filing for Q4 2021, filed 8 Feb 2022.